At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MIRA Mira Pharma
Trading 07-15 12:25:19 EDT
0.9401
+0.0300
+3.30%
High0.9500Low0.9157Vol31.39K
Open0.9349D1 Closing0.9101Amplitude3.77%
Mkt Cap39.37MTradable Cap32.85MTotal Shares41.88M
T/O29.39KT/O Rate0.09%Tradable Shares34.94M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies
MT Newswires Live  ·  07-10
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Mira-55 - SEC Filing
THOMSON REUTERS  ·  07-10
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Mira-55 - SEC Filing
Mira Pharmaceuticals Announces Release of Mira-55 Oral Formulation Update
Reuters  ·  07-10
Mira Pharmaceuticals Announces Release of Mira-55 Oral Formulation Update
MIRA Reports Positive Preclinical Data for SKNY-1 Program
TIPRANKS  ·  07-06
MIRA Reports Positive Preclinical Data for SKNY-1 Program
Mira Pharmaceuticals reports SKNY-1 formulation results
TIPRANKS  ·  07-06
Mira Pharmaceuticals reports SKNY-1 formulation results
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Skny-1 - SEC Filing
THOMSON REUTERS  ·  07-06
Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Skny-1 - SEC Filing
Mira Pharmaceuticals - Skny-1 Shows Favorable Bioavailability, Robust Brain and Liver Exposure, Once-daily Dosing Potential - SEC Filing
THOMSON REUTERS  ·  07-06
Mira Pharmaceuticals - Skny-1 Shows Favorable Bioavailability, Robust Brain and Liver Exposure, Once-daily Dosing Potential - SEC Filing
Mira Pharmaceuticals Reports Positive Preclinical Oral Formulation Results for Obesity, Addiction Drug Candidate Skny-1
Reuters  ·  07-06
Mira Pharmaceuticals Reports Positive Preclinical Oral Formulation Results for Obesity, Addiction Drug Candidate Skny-1
Mira Pharma Reports Preclinical Study Showing Mira-55 Reduces Anxiety-like Behavior, Differs from THC Mechanism
Reuters  ·  06-25
Mira Pharma Reports Preclinical Study Showing Mira-55 Reduces Anxiety-like Behavior, Differs from THC Mechanism
Mira Pharmaceuticals - Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 - SEC Filing
THOMSON REUTERS  ·  06-17
Mira Pharmaceuticals - Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 - SEC Filing
Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy
Reuters  ·  06-17
Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy
Mira Pharmaceuticals CFO Andriy Mushak files initial beneficial ownership statement
Reuters  ·  06-10
Mira Pharmaceuticals CFO Andriy Mushak files initial beneficial ownership statement
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer
TIPRANKS  ·  06-09
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer
BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Reuters  ·  06-09
BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Mira Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum
Reuters  ·  06-09
Mira Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum
MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline
TIPRANKS  ·  06-04
MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline
Mira Pharmaceuticals Inc: Controls Global Development Rights Across Entire Pipeline
THOMSON REUTERS  ·  06-04
Mira Pharmaceuticals Inc: Controls Global Development Rights Across Entire Pipeline
Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal
Reuters  ·  06-04
Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal
MIRA Expands Global Ketamir-2 License for Clinical Development
TIPRANKS  ·  05-27
MIRA Expands Global Ketamir-2 License for Clinical Development
Mira Pharmaceuticals Inc: Entered Into Amendment No 1 to Exclusive License Agreement With Miralogx Llc - SEC Filing
THOMSON REUTERS  ·  05-27
Mira Pharmaceuticals Inc: Entered Into Amendment No 1 to Exclusive License Agreement With Miralogx Llc - SEC Filing

Introduction

Company Name.
Mira Pharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Issue price:
--